GLK-221 eye drops for keratoconus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, randomized, parallel-group, placebo-controlled trial testing twice-daily topical GLK-221 versus matching placebo in adults with keratoconus. Participants are adults aged 18 to 55 with a diagnosis of keratoconus in the study eye and will be followed for safety and efficacy outcomes. The trial is run by Glaukos at clinical sites and uses standard ophthalmic assessments such as corneal shape and visual function measures to gauge effect. Safety monitoring will track ocular and systemic adverse events throughout the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be ≥ 18 and ≤ 55 years of age
* Diagnosis of keratoconus in the study eye

Exclusion Criteria:

* Pregnant, lactating or planning a pregnancy
* Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Where it's running

• Glaukos Clinical Study Site
  Westerville, Ohio, United States Recruiting

Study contacts

• Study coordinator: Study Manager
• Email: ClinicalResearch@Glaukos.com
• Phone: 949-739-8749

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Corneal Crosslinking to Treat Progressive Keratoconus or Corneal Ectasia

  This study tests two different light durations used in corneal crosslinking to see which better helps people with keratoconus or corneal ectasia.

  Recruiting Phase 2/3 Price Vision Group · Indianapolis, Indiana · NCT07841470

• Brillouin hydration mapping to study cornea health

  Researchers test a Brillouin microscope to see if it can measure corneal water content in healthy people and those with eye conditions.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07780890

• Same-day bilateral corneal cross-linking for keratoconus

  This trial tests whether performing corneal cross-linking in both eyes on the same day is safe and feasible for people with keratoconus.

  Recruiting Phase 4 Glaukos Corporation · Westerville, Ohio · NCT07629557

• A Smart Aperture Lens to Help Keratoconus and Presbyopia

  This study tests the NOA lens, a custom scleral contact lens with a central aperture, to see if it improves vision for people with keratoconus and presbyopia.

  Recruiting at 2 sites Azalea Vision · Antwerp and 1 other locations · NCT07559188

• Corneal wavefront-guided PRK plus epi-off CXL versus PTK plus epi-off CXL for keratoconus

  This trial tests whether adding corneal wavefront-guided PRK to epi-off corneal cross-linking gives better vision than PTK plus epi-off CXL in adults with keratoconus.

  Recruiting Instituto de Oftalmología Fundación Conde de Valenciana · Mexico City, Mexico City · NCT07372911

• Epi-ON corneal crosslinking with UVA for people with Down syndrome and corneal ectasia

  This trial will try Epi-ON corneal crosslinking (riboflavin drops plus UVA light) to see if it can slow or stop corneal thinning and vision loss in people with Down syndrome who have keratoconus or similar ectatic corneal conditions.

  Recruiting at 12 sites Phase 3 Woolfson Eye Institute · Atlanta, Georgia and 11 other locations · NCT07135167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.